Delcath Systems Beats Q2 Estimates, Raises Full-Year Guidance on HEPZATO Momentum
DCTH sits 72% above its 52-week low of $8.12.
Summary
Delcath Systems reported Q2 revenue of $29.1M, beating estimates by 11%, and raised full-year 2026 guidance to $104M–$108M. Net income reached $2.7M, with cash and investments of $95.9M.
Key Events · Earnings and Guidance · DCTH
-
Q2 Revenue Beat
Revenue of $29.1M exceeded the $26.3M consensus by 11%, driven by HEPZATO KIT sales of $27.2M.
-
Full-Year Guidance Raised
Management lifted 2026 revenue guidance to $104M–$108M, up from prior expectations, reflecting strong demand and commercial execution.
-
Return to Profitability
Net income was $2.7M for Q2, compared to $2.7M a year ago, as gross margin expanded to 89.8% on higher sales.
-
Strong Balance Sheet
Cash, equivalents, and short-term investments totaled $95.9M at quarter-end, with no debt, providing ample runway for clinical trials and operations.
Analysis · DCTH · Industrial Applications And Services
A strong Q2 for Delcath Systems saw revenue of $29.1 million beat consensus by 11%, prompting management to raise full-year guidance to $104–$108 million. The company swung to a net profit of $2.7 million, supported by expanding HEPZATO adoption and a healthy cash position of $95.9 million. These results confirm commercial traction for its liver-directed cancer therapy and provide a clear growth trajectory, though operating expenses are rising as clinical trials expand.
At the time of this filing, DCTH was trading at $14.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $436M. The 52-week trading range was $8.12 to $13.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.